Answers are grounded in this paper and cite their sources.
Double-blind randomized placebo-controlled trial investigates HIV rebound timing after therapy interruption, suggesting new ART-free remission approaches.
Long-acting bNAbs can sustain extended ART-free viral control in people treated during early-stage HIV and represent a promising step towards achieving ART-free HIV remission.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.